Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas

Cairo University70 enrolled

Overview

in this resarch we will use ELISA Technique to estimate Human Transcriptional Activator(MYB) Expression .compare it by Immmunohistochemistry analysis of MYB Expression in the malignant and benign salivary gland tumor

Study Type

OBSERVATIONAL

Enrollment

Conditions

Malignant Neoplasm of Salivary Gland Benign Neoplasm of Salivary Gland

Interventions

enzyme linked immunosorbent assay (ELISA)DEVICE

ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: . * Patients with clinically evident salivary gland tumors; malignant tumors will be recruited in group I * Benign tumors will be recruited in group II. Exclusion Criteria: * Subjects taking any drugs inducing any changes that could affect the salivary glands. * Pregnant females. * Subjects having any allergies, infectious or autoimmune diseases. * Subjects having any metabolic disorders that can be manifested with salivary gland swelling as diabetes mellitus.

Locations (1)

National Cancer Institute

Cairo, Egypt

RECRUITING

Outcomes

Primary Outcomes

Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas

Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas.

Time frame: two years

Central Contacts

yousra refaey

CONTACT

01014458092 yousrarefaey@yahoo.com

Fat'heya Zahran

CONTACT

01060775113 fatheya.zahran@dentistry.cu.edu.eg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.